Skip to main content

ResMed Inc. (RMD) Stock Analysis

Falling Knife setup · Temp Headwind edge

Buy WaitVALUE-TRAP 2/5Moderate Confidence

Healthcare · Medical Instruments & Supplies

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait — supporting gate not met yet. Price is at or below entry $219.31 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risk: Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow.

ResMed designs and sells cloud-connected medical devices for sleep apnea and COPD, plus residential care software for HME/DME, home health, skilled nursing, and hospice providers, in 140+ countries through two segments: Sleep and Breathing Health and Residential Care Software.... Read more

$210.94+26.1% A.UpsideScore 5.9/10#4 of 25 Medical Instruments & Supplies
Entry $219.31(Atr Pullback Sticky)Stop $209.22Target $260.94(analyst − 10%)A.R:R 4.6:1
Analyst target$289.93+37.4%15 analysts
$260.94our TP
$210.94price
$289.93mean
$345

Wait — supporting gate not met yet. Price is at or below entry $219.31 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risk: Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow. Chart setup: Death cross, below all MAs, RSI 27, MACD bearish. Earnings in 0 days. Wait until post-earnings. Score 5.9/10, moderate confidence.

Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 0d<=7d. Suitability: moderate.

Val6.1Qual8.7Grw5.1Mom2.0Sent7.1Ins5.0Peer4.8Tech8.2Risk6.05.9OVERALL

Thesis

Rewards
No bull case signals
Risks
Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow

Key Metrics

P/E (TTM)21.0
P/E (Fwd)17.4
Mkt Cap$30.9B
EV/EBITDA15.0
Profit Mgn27.5%
ROE25.7%
Rev Growth11.0%
Beta0.93
Dividend1.13%
Rating analysts25

Quality Signals

Piotroski F9/9

Options Flow

P/C0.27bullish
IV68%elevated
Max Pain$300+42.2% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
1.0
Rsi
3.0
Volume
5.2
Capitulation risk (RSI 27, below 200MA)Volume distribution (falling OBV)Below 200-MA, MA slope -1.5%/30d — confirmed downtrend
GatesMomentum 2.0<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 0d<=7dA.R:R 4.6 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARFalling KnifeSuitability: Moderate
RSI
27 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $211.93Resistance $234.91

Price Targets

$209
$219
$261
A.Upside+23.7%
A.R:R4.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Earnings in 0 days - binary event risk
! Momentum score 2.0/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is RMD stock a buy right now?

Wait — supporting gate not met yet. Price is at or below entry $219.31 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risk: Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow. Chart setup: Death cross, below all MAs, RSI 27, MACD bearish. Earnings in 0 days. Wait until post-earnings. Target $260.94 (+23.7%), stop $209.22 (−0.8%), Setup A.R:R 5.3:1. Score 5.9/10, moderate confidence.

What is the RMD stock price target?

Take-profit target: $260.94 (+26.1% upside). Target $260.94 (+23.7%), stop $209.22 (−0.8%), Setup A.R:R 5.3:1. Stop-loss: $209.22.

What are the risks of investing in RMD?

Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow.

Is RMD overvalued or undervalued?

ResMed Inc. trades at a P/E of 21.0 (forward 17.4). TrendMatrix value score: 6.1/10. Verdict: Buy (Wait for Entry).

What do analysts say about RMD?

25 analysts cover RMD with a consensus score of 3.7/5. Average price target: $290.

What does ResMed Inc. do?ResMed designs and sells cloud-connected medical devices for sleep apnea and COPD, plus residential care software for...

ResMed designs and sells cloud-connected medical devices for sleep apnea and COPD, plus residential care software for HME/DME, home health, skilled nursing, and hospice providers, in 140+ countries through two segments: Sleep and Breathing Health and Residential Care Software. Revenue is generated from device and software sales globally; approximately 64% from the U.S. and 36% from Europe, Asia, and other regions in fiscal 2025. The company employs 10,600+ people and acquired VirtuOx, a sleep/respiratory diagnostics IDTF, in May 2025.

Related stocks: WST (West Pharmaceutical Services, I) · ISRG (Intuitive Surgical, Inc.) · MMSI (Merit Medical Systems, Inc.) · STVN (Stevanato Group S.p.A.) · SOLV (Solventum Corporation)